Background: About 5% of NSCLC cases present with anaplastic lymphoma kinase (ALK) fusions and are candidates for an ALK tyrosine kinase inhibitor (ALKi). Evidence on real-world adherence and persistence of ALKi is limited. Objectives: Estimate adherence and persistence of in NSCLC. Results: This study analyzed 1482 patients whose first ALKi was alectinib or crizotinib (n=445 and 1037, respectively) and 880 patients with subsequent ALKis (604 alectinib, 142 brigatinib, 134 ceritinib). Adherence during treatment period (95-97%) and proportions of MPR ³0.8 (92-95%) were similar across all ALKis. Real-world median time to discontinuation was 27.4 vs 8.9 months for alectinib vs crizotinib in the first ALKi cohort. Patients using alectinib as first ALKi were 46% less likely to discontinue ALKi than crizotinib patients (adjusted hazard ratio (aHR) [95% CI]: 0.54 [0.44-0.65]). For subsequent ALKi use, the risk of discontinuation for alectinib was 64% lower vs ceritinib (aHR [95% CI]: 0.36 [0.2..... READ ARTICLE
Journal of the National Comprehensive Cancer Network DOI:10.6004/jnccn.2019.7501
Authors: Ganti, A. K., Ogale, S., Yang, E., & Wong, W.
